Drugs / lerodalcibep
Trials 12 · a red edge is where a trial was stopped
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03545438 Comparator | Oct 2017 → May 2018 | hyperlipidemia | LIB Therapeutics LLC | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07102511 Comparator | Sep 2025 → Dec 2026 expected | familial hypercholesterolemia | LIB Therapeutics LLC | Not yet recruiting | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 15 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lerodalcibep | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06568471 ↗ |
| Known as | HST101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06504043 ↗ |
| Known as | Lerochol | “monthly dosing of lerodalcibep (Lerochol) 300 mg administered subcutaneously by auto-injector (AI)/pre-filled pen (PFP)” NCT07102511 ↗ |
| Known as | LIB003 | “LIB003 (lerodalcibep) Process 1” NCT05234775 ↗ |
| Action | Inhibit | “Lerodalcibep and evolocumab for the treatment of homozygous familial hypercholesterolaemia with PCSK9 inhibition” PMID 39870096 ↗ Jan 2025 |
| Modality | Protein / enzyme biologic | “Lerodalcibep, a small binding anti-PCSK9 protein (adnectin)” PMID 39870096 ↗ Jan 2025 |
| Route | Subcutaneous | “by SC injection” NCT03545438 ↗ |
| Target | PCSK9 | “Lerodalcibep, a small binding anti-PCSK9 protein (adnectin)” PMID 39870096 ↗ Jan 2025 |